Immix Biopharma Inc (IMMX)

Currency in USD
6.960
-0.080(-1.14%)
Closed·
6.9600.000(0.00%)
·
IMMX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
6.9007.500
52 wk Range
3.78015.100
Key Statistics
Prev. Close
7.04
Open
7
Day's Range
6.9-7.5
52 wk Range
3.78-15.1
Volume
1.57M
Average Volume (3m)
1.45M
1-Year Change
60.739%
Book Value / Share
4.04
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IMMX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
23.913
Upside
+243.57%
Members' Sentiments
Bearish
Bullish
ProTips
4 analysts have revised their earnings upwards for the upcoming period

Immix Biopharma Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 23.913
(+243.57% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Morgan Stanley
Buy21.00+201.72%20.00MaintainNov 18, 2026
Mizuho
Buy22.00+216.09%23.00MaintainNov 18, 2026
H.C. Wainwright
Buy27.00+287.93%25.00MaintainNov 16, 2026
Mizuho
Buy23.00+230.46%26.00MaintainOct 29, 2026
Morgan Stanley
Buy20.00+187.36%-New CoverageOct 20, 2026

Earnings

Latest Release
Nov 13, 2026
EPS / Forecast
-0.19 / -0.19
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

IMMX Income Statement

Compare IMMX to Peers and Sector

Metrics to compare
IMMX
Peers
Sector
Relationship
P/E Ratio
−12.6x−7.0x−0.2x
PEG Ratio
6.870.030.00
Price/Book
1.7x2.0x2.6x
Price / LTM Sales
-31.1x2.6x
Upside (Analyst Target)
243.6%141.6%76.9%
Fair Value Upside
Unlock−8.2%14.9%Unlock

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company’ lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
18.76M22.62%133.35M
Other Institutional Investors
46.31M55.86%329.25M
Public Companies & Retail Investors
17.84M21.52%126.83M
Total
82.9M100.00%589.44M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Janus Henderson Group Ltd.11.80%9,783,19269,558
Saturn V Capital Management LP5.62%4,658,42933,121

People Also Watch

88.91
ANT
-8.50%
13.660
SLS
-8.08%
36.05
PENG
-15.20%
32.930
AAOI
-16.55%

FAQ

What Is the Immix Biopharma (IMMX) Stock Price Today?

The Immix Biopharma stock price today is 6.960 USD.

What Stock Exchange Does Immix Biopharma Trade On?

Immix Biopharma is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Immix Biopharma?

The stock symbol for Immix Biopharma is "IMMX."

What Is the Immix Biopharma Market Cap?

As of today, Immix Biopharma market cap is 590.040M USD.

What Is Immix Biopharma's Earnings Per Share (TTM)?

The Immix Biopharma EPS (TTM) is -0.79.

When Is the Next Immix Biopharma Earnings Date?

Immix Biopharma will release its next earnings report on Mar 03, 2027.

From a Technical Analysis Perspective, Is IMMX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Immix Biopharma Stock Split?

Immix Biopharma has split 0 times.

What is the current trading status of Immix Biopharma (IMMX)?

As of Nov 21, 2026, Immix Biopharma (IMMX) is trading at a price of 6.960 USD, with a previous close of 7.040 USD. The stock has fluctuated within a day range of 6.900 USD to 7.500 USD, while its 52-week range spans from 3.780 USD to 15.100 USD.

What Is Immix Biopharma (IMMX) Price Target According to Analysts?

The average 12-month price target for Immix Biopharma is 23.913 USD, with a high estimate of 30 USD and a low estimate of 16.3 USD. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +243.57% Upside potential.

What Is the IMMX Premarket Price?

IMMX's last pre-market stock price is 7.210 USD. The pre-market share volume is 17,360.000, and the stock has decreased by 0.170, or 2.410%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.